IBDEI12H ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18830,2)
 ;;=^269821
 ;;^UTILITY(U,$J,358.3,18831,0)
 ;;=397.1^^105^1222^74
 ;;^UTILITY(U,$J,358.3,18831,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18831,1,4,0)
 ;;=4^397.1
 ;;^UTILITY(U,$J,358.3,18831,1,5,0)
 ;;=5^Rheumatic Disease Pulmonary Valve
 ;;^UTILITY(U,$J,358.3,18831,2)
 ;;=^269587
 ;;^UTILITY(U,$J,358.3,18832,0)
 ;;=397.0^^105^1222^75
 ;;^UTILITY(U,$J,358.3,18832,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18832,1,4,0)
 ;;=4^397.0
 ;;^UTILITY(U,$J,358.3,18832,1,5,0)
 ;;=5^Rheumatic Disease Tricuspid Valve
 ;;^UTILITY(U,$J,358.3,18832,2)
 ;;=^35528
 ;;^UTILITY(U,$J,358.3,18833,0)
 ;;=414.3^^105^1222^17
 ;;^UTILITY(U,$J,358.3,18833,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18833,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,18833,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,18833,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,18834,0)
 ;;=414.4^^105^1222^16
 ;;^UTILITY(U,$J,358.3,18834,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18834,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,18834,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,18834,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,18835,0)
 ;;=425.11^^105^1222^60
 ;;^UTILITY(U,$J,358.3,18835,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18835,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,18835,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,18835,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,18836,0)
 ;;=425.18^^105^1222^59
 ;;^UTILITY(U,$J,358.3,18836,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18836,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,18836,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,18836,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,18837,0)
 ;;=V12.55^^105^1222^54
 ;;^UTILITY(U,$J,358.3,18837,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18837,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,18837,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,18837,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,18838,0)
 ;;=454.9^^105^1222^84
 ;;^UTILITY(U,$J,358.3,18838,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18838,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,18838,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,18838,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,18839,0)
 ;;=271.3^^105^1223^11
 ;;^UTILITY(U,$J,358.3,18839,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18839,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,18839,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,18839,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,18840,0)
 ;;=611.1^^105^1223^16
 ;;^UTILITY(U,$J,358.3,18840,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18840,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,18840,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,18840,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,18841,0)
 ;;=704.1^^105^1223^17
 ;;^UTILITY(U,$J,358.3,18841,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18841,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,18841,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,18841,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,18842,0)
 ;;=251.2^^105^1223^30
 ;;^UTILITY(U,$J,358.3,18842,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18842,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,18842,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,18842,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,18843,0)
 ;;=253.2^^105^1223^34
 ;;^UTILITY(U,$J,358.3,18843,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18843,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,18843,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,18843,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,18844,0)
 ;;=733.00^^105^1223^43
 ;;^UTILITY(U,$J,358.3,18844,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI12H
